Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average recommendation of “Moderate Buy” from the twenty brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $183.89.

Several research firms have issued reports on SRPT. Citigroup cut their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Bank of America boosted their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research note on Friday, June 21st. Needham & Company LLC restated a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research note on Monday. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, Robert W. Baird raised their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, June 21st.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $124.25 on Friday. The firm’s 50 day moving average price is $128.96 and its 200-day moving average price is $132.33. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $11.74 billion, a PE ratio of 1,129.55 and a beta of 0.82. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the firm earned ($0.27) earnings per share. The company’s quarterly revenue was up 38.9% on a year-over-year basis. Equities research analysts expect that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. boosted its holdings in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares during the period. Innealta Capital LLC bought a new position in Sarepta Therapeutics in the 2nd quarter valued at $31,000. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics in the first quarter worth $32,000. Finally, GAMMA Investing LLC lifted its position in shares of Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.